Senseonics Holdings, Inc. (SENS)
| Market Cap | 330.97M -31.3% |
| Revenue (ttm) | 40.71M +71.9% |
| Net Income | -87.19M |
| EPS | -1.98 |
| Shares Out | 52.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 601,150 |
| Open | 6.18 |
| Previous Close | 6.34 |
| Day's Range | 6.18 - 6.60 |
| 52-Week Range | 4.79 - 12.58 |
| Beta | 1.06 |
| Analysts | Buy |
| Price Target | 16.67 (+162.93%) |
| Earnings Date | May 7, 2026 |
About SENS
Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company ser... [Read more]
Financial Performance
In 2025, Senseonics Holdings's revenue was $35.26 million, an increase of 56.89% compared to the previous year's $22.47 million. Losses were -$69.11 million, -12.09% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for SENS stock is "Buy." The 12-month stock price target is $16.67, which is an increase of 162.93% from the latest price.
News
Senseonics Holdings Transcript: AGM 2026
The meeting, held virtually, covered six proposals including director elections, executive compensation, auditor ratification, share authorization increase, and an equity plan. All proposals passed, with results to be reported on Form 8-K.
Senseonics price target lowered to $14 from $18.50 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Senseonics (SENS) to $14 from $18.50 and keeps a Buy rating on the shares. The firm cites equity dilution for the target…
Senseonics price target lowered to $8 from $9 at Stifel
Stifel analyst Jonathan Block lowered the firm’s price target on Senseonics (SENS) to $8 from $9 and keeps a Hold rating on the shares following what the firm calls “a…
Senseonics Holdings, Inc. Common Stock Q1 Earnings Call Highlights
Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue outlook after reporting first-quarter growth tied to adoption of its Eversense 365 continuous glucose monitoring s...
Senseonics price target lowered to $12 from $20 at Lake Street
Lake Street analyst Ben Haynor lowered the firm’s price target on Senseonics (SENS) to $12 from $20 and keeps a Buy rating on the shares after the company reported a…
Senseonics reports Q1 EPS (71c), consensus (70c)
Reports Q1 revenue $9.34M, consensus $9.83M. Tim Goodnow, President and Chief Executive Officer of Senseonics (SENS), said, “This was our first quarter as a fully-integrated commercial organization in...
Senseonics Holdings Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 85% year-over-year to $11.7M with gross margin at 58%, driven by strong Eversense 365 adoption and successful U.S. commercial integration. Full-year revenue guidance was raised, and over $100M in new capital was secured to support growth and product pipeline.
Senseonics Holdings Earnings release: Q1 2026
Senseonics Holdings released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Senseonics Holdings Quarterly report: Q1 2026
Senseonics Holdings has published its Q1 2026 quarterly earnings report on May 7, 2026.
Senseonics Holdings, Inc. Reports First Quarter 2026 Financial Results
Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress, includ...
Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implanta...
Senseonics Enters Into Amended Loan Agreement with Hercules to Increase Borrowing Capacity to $140 Million
GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the design, development and commercialization of glucose monitoring p...
Senseonics Holdings, Inc. Schedules First Quarter 2026 Earnings Release and Conference Call for May 7, 2026 at 4:30 P.M. Eastern Time
GERMANTOWN, Md., May 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, im...
Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term,...
Senseonics announces common stock offering, no amount given
Senseonics (SENS) Holdings announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock and, to certain…
Senseonics Announces Commencement of $80 Million Public Offering of Common Stock and Pre-Funded Warrants
GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term,...
Senseonics Announces European Launch of Eversense® 365, The World's First and Only One Year CGM System
The next-generation CGM is now available in Sweden, with launches expected in Germany, Spain and Italy during the coming weeks as part of a phased roll out
Senseonics Holdings Proxy statement: Proxy filing
Senseonics Holdings filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
Senseonics Holdings Proxy statement: Proxy filing
Senseonics Holdings filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Senseonics Holdings Proxy statement: Proxy filing
Senseonics Holdings filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Senseonics Holdings Proxy statement: Proxy filing
Senseonics Holdings filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear
New data shows positive real-world impact of the world's first and only one-year CGM, with a full year of strong patient adherence, glucometrics and hypoglycemic outcomes
Senseonics Holdings Earnings Call Transcript: Q4 2025
Revenue grew 60% to $35.3M in 2025, with gross margin over 50% and patient base doubling in the U.S. The company expects 65–76% revenue growth in 2026, driven by European expansion, new product launches, and continued DTC investment.
Senseonics Holdings Annual report: Q4 2025
Senseonics Holdings has published its Q4 2025 annual report on March 2, 2026.
Senseonics Holdings Earnings release: Q4 2025
Senseonics Holdings released its Q4 2025 earnings on March 2, 2026, summarizing the period's financial results.